News Releases - Rapid Micro Biosystems, Inc.

Year

03 05 / 2024

Rapid Micro Biosystems Reports First Quarter 2024 Financial Results

Reports first quarter 2024 total revenue of $5.6 million , representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE)

18 04 / 2024

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024

LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will

19 03 / 2024

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024

Company to give technical presentation on its innovative Growth Direct® Rapid Sterility Application LOWELL, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation

12 03 / 2024

Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

06 03 / 2024

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

01 03 / 2024

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

Reports fourth quarter 2023 total revenue of $6.3 million , representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million , representing 31% growth compared to 2022 Delivered 2023 recurring revenue of $13.5 million , representing 23% growth compared to 2022 Provides

27 02 / 2024

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

LOWELL, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today

20 02 / 2024

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will

10 01 / 2024

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism detection in as little as 12 hours and final time-to-result in as little as one to three days Commercial

10 01 / 2024

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue

Full year 2023 total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year Fourth quarter 2023 total revenue expected to be between $6.2 million and $6.4 million, representing growth of approximately 45% compared to the prior-year

Pagination

Current page 1
Page 2
Next page
Last page